{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:29:24Z","timestamp":1787498964762,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,24]]},"DOI":"10.7759\/cureus.29533","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T12:40:26Z","timestamp":1664023226000},"source":"Crossref","is-referenced-by-count":14,"title":["Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials"],"prefix":"10.7759","author":[{"given":"Vaibhavi B","family":"Wasnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana R","family":"Thool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Approved cellular and gene therapy products | FDA. (2022). Accessed. August 19, 2022: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302030","article-title":"Immune response following intraocular delivery of recombinant viral vectors","volume":"10","author":"Bennett J","year":"2003","unstructured":"Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther. 2003, 10:977-82. 10.1038\/sj.gt.3302030","journal-title":"Gene Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.750586","article-title":"Gene therapy in inherited retinal diseases: an update on current state of the art","volume":"8","author":"Amato A","year":"2021","unstructured":"Amato A, Arrigo A, Aragona E, Manitto MP, Saladino A, Bandello F, Battaglia Parodi M. Gene therapy in inherited retinal diseases: an update on current state of the art. Front Med (Lausanne). 2021, 8:750586. 10.3389\/fmed.2021.750586","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/10443.5394","article-title":"Non viral vectors in gene therapy - an overview","volume":"9","author":"Ramamoorth M","year":"2015","unstructured":"Ramamoorth M, Narvekar A. Non viral vectors in gene therapy - an overview. J Clin Diagn Res. 2015, 9:GE01-6. 10.7860\/JCDR\/2015\/10443.5394","journal-title":"J Clin Diagn Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2012.10.004","article-title":"Corneal gene therapy: basic science and translational perspective","volume":"11","author":"Mohan RR","year":"2013","unstructured":"Mohan RR, Rodier JT, Sharma A. Corneal gene therapy: basic science and translational perspective. Ocul Surf. 2013, 11:150-64. 10.1016\/j.jtos.2012.10.004","journal-title":"Ocul Surf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118712","article-title":"Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: recent advancements and future perspectives","volume":"264","author":"Naik S","year":"2021","unstructured":"Naik S, Shreya AB, Raychaudhuri R, et al.. Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: recent advancements and future perspectives. Life Sci. 2021, 264:118712. 10.1016\/j.lfs.2020.118712","journal-title":"Life Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090654","article-title":"Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges","volume":"10","author":"V\u00e1zquez-Dom\u00ednguez I","year":"2019","unstructured":"V\u00e1zquez-Dom\u00ednguez I, Garanto A, Collin RW. Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges. Genes (Basel). 2019, 10:10.3390\/genes10090654","journal-title":"Genes (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell S","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, et al.. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017, 390:849-60. 10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet"},{"key":"ref9","article-title":"The CRISPR\/Cas9 system for gene editing and its potential application in pain research","volume":"1","author":"Sun L","year":"2016","unstructured":"Sun L, Lutz BM, Tao YX. The CRISPR\/Cas9 system for gene editing and its potential application in pain research. Transl Perioper Pain Med. 2016, 1:22-33.","journal-title":"Transl Perioper Pain Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.001","article-title":"Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa","volume":"125","author":"Tsai YT","year":"2018","unstructured":"Tsai YT, Wu WH, Lee TT, et al.. Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa. Ophthalmology. 2018, 125:1421-30. 10.1016\/j.ophtha.2018.04.001","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023754","article-title":"Genome-editing technologies: principles and applications","volume":"8","author":"Gaj T","year":"2016","unstructured":"Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol. 2016, 8:10.1101\/cshperspect.a023754","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas P","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, et al.. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014, 370:901-10. 10.1056\/NEJMoa1300662","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez A","year":"2013","unstructured":"Guzman-Aranguez A, Loma P, Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013, 170:730-47. 10.1111\/bph.12330","journal-title":"Br J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-020-1736-7","article-title":"Antisense oligonucleotides: a unique treatment approach","volume":"57","author":"Krishnan AV","year":"2020","unstructured":"Krishnan AV, Mishra D. Antisense oligonucleotides: a unique treatment approach. Indian Pediatr. 2020, 57:165-171. 10.1007\/s13312-020-1736-7","journal-title":"Indian Pediatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell SR","year":"2022","unstructured":"Russell SR, Drack AV, Cideciyan AV, et al.. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial. Nat Med. 2022, 28:1014-21. 10.1038\/s41591-022-01755-w","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1296-1316","article-title":"Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+\/- mice","volume":"2","author":"Riley DJ","year":"1996","unstructured":"Riley DJ, Nikitin AY, Lee WH. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+\/- mice. Nat Med. 1996, 2:1316-21. 10.1038\/nm1296-1316","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081605","article-title":"Lentiviral vectors for ocular gene therapy","volume":"14","author":"Arsenijevic Y","year":"2022","unstructured":"Arsenijevic Y, Berger A, Udry F, Kostic C. Lentiviral vectors for ocular gene therapy. Pharmaceutics. 2022, 14:10.3390\/pharmaceutics14081605","journal-title":"Pharmaceutics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","volume":"16","author":"Ghoraba HH","year":"2022","unstructured":"Ghoraba HH, Akhavanrezayat A, Karaca I, et al.. Ocular gene therapy: a literature review with special focus on immune and inflammatory responses. Clin Ophthalmol. 2022, 16:1753-71. 10.2147\/OPTH.S364200","journal-title":"Clin Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh S","year":"2020","unstructured":"Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf. 2020, 25:7-18. 10.1177\/1535676019899502","journal-title":"Appl Biosaf"},{"key":"ref20","unstructured":"National Library of Medicine (U.S.) ClinicalTrials.gov. (2022). Accessed. August 6, 2022: http:\/\/ClinicalTrials.gov."},{"key":"ref21","unstructured":"Safety and efficacy study in subjects with Leber congenital amaurosis - full-text view - ClinicalTrials.gov. (2022). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00999609?term=NCT00999609&draw=2&rank=1."},{"key":"ref22","unstructured":"Dose-escalation study to evaluate the safety and tolerability of GS030 in subjects with retinitis pigmentosa. (2022). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03326336."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel JA","year":"2021","unstructured":"Sahel JA, Boulanger-Scemama E, Pagot C, et al.. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021, 27:1223-9. 10.1038\/s41591-021-01351-4","journal-title":"Nat Med"},{"key":"ref24","unstructured":"A study to evaluate the safety and tolerability of QR-1123 in subjects with autosomal dominant retinitis pigmentosa due to the P23H mutation in the RHO gene. (2019). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04123626."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3679-9","article-title":"A novel MERTK mutation causing retinitis pigmentosa","volume":"255","author":"Al-Khersan H","year":"2017","unstructured":"Al-Khersan H, Shah KP, Jung SC, Rodriguez A, Madduri RK, Grassi MA. A novel MERTK mutation causing retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2017, 255:1613-9. 10.1007\/s00417-017-3679-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref26","unstructured":"Trial of subretinal injection of (rAAV2-VMD2-hMERTK). (2021). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01482195."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.050","article-title":"Gene transfer for neovascular age-related macular degeneration","volume":"22","author":"Campochiaro PA","year":"2011","unstructured":"Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Hum Gene Ther. 2011, 22:523-9. 10.1089\/hum.2011.050","journal-title":"Hum Gene Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316195","article-title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","volume":"105","author":"Guimaraes TA","year":"2021","unstructured":"Guimaraes TA, Georgiou M, Bainbridge JW, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br J Ophthalmol. 2021, 105:151-7. 10.1136\/bjophthalmol-2020-316195","journal-title":"Br J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene therapy intervention in neovascular eye disease: a recent update","volume":"28","author":"Lin FL","year":"2020","unstructured":"Lin FL, Wang PY, Chuang YF, Wang JH, Wong VH, Bui BV, Liu GS. Gene therapy intervention in neovascular eye disease: a recent update. Mol Ther. 2020, 28:2120-38. 10.1016\/j.ymthe.2020.06.029","journal-title":"Mol Ther"},{"key":"ref30","unstructured":"Study of AdGVPEDF.11D in neovascular age-related macular degeneration (AMD). (2005). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00109499."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro PA","year":"2006","unstructured":"Campochiaro PA, Nguyen QD, Shah SM, et al.. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006, 17:167-76. 10.1089\/hum.2006.17.167","journal-title":"Hum Gene Ther"},{"key":"ref32","unstructured":"ADVM-022 intravitreal gene therapy for Wet AMD (OPTIC). (2018). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03748784."},{"key":"ref33","unstructured":"Phase I dose escalation safety study of retinostat in advanced age-related macular degeneration (AMD) - full text view - ClinicalTrials.gov. (2011). Accessed. August 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01301443."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro PA","year":"2017","unstructured":"Campochiaro PA, Lauer AK, Sohn EH, et al.. Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum Gene Ther. 2017, 28:99-111. 10.1089\/hum.2016.117","journal-title":"Hum Gene Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable IJ","year":"2016","unstructured":"Constable IJ, Pierce CM, Lai CM, et al.. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine. 2016, 14:168-75. 10.1016\/j.ebiom.2016.11.016","journal-title":"EBioMedicine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier JS","year":"2017","unstructured":"Heier JS, Kherani S, Desai S, et al.. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017, 390:50-61. 10.1016\/S0140-6736(17)30979-0","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta N","year":"2021","unstructured":"Mehta N, Robbins DA, Yiu G. Ocular inflammation and treatment emergent adverse events in retinal gene therapy. Int Ophthalmol Clin. 2021, 61:151-77. 10.1097\/IIO.0000000000000366","journal-title":"Int Ophthalmol Clin"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.153","article-title":"Ocular gene delivery using lentiviral vectors","volume":"19","author":"Balaggan KS","year":"2012","unstructured":"Balaggan KS, Ali RR. Ocular gene delivery using lentiviral vectors. Gene Ther. 2012, 19:145-53. 10.1038\/gt.2011.153","journal-title":"Gene Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers AM","year":"2020","unstructured":"Timmers AM, Newmark JA, Turunen HT, et al.. Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid. Hum Gene Ther. 2020, 31:80-9. 10.1089\/hum.2019.144","journal-title":"Hum Gene Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110149-ocular-gene-therapy-a-literature-review-with-focus-on-current-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:48:53Z","timestamp":1707490133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110149-ocular-gene-therapy-a-literature-review-with-focus-on-current-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.29533","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,24]]}}}